Holen Sie sich die Stockscreener-App
22.94
0.26%
-0.06
Handel nachbörslich:
22.94
Schlusskurs vom Vortag:
$23.00
Offen:
$23.02
24-Stunden-Volumen:
309.14K
Relative Volume:
0.95
Marktkapitalisierung:
$1.56B
Einnahmen:
$350.00K
Nettoeinkommen (Verlust:
$-72.78M
KGV:
-21.24
EPS:
-1.08
Netto-Cashflow:
$-54.46M
1W Leistung:
+16.86%
1M Leistung:
+26.46%
6M Leistung:
+17.94%
1J Leistung:
+52.12%
1-Tages-Spanne:
$22.64
$23.48
1-Wochen-Bereich:
$19.98
$23.66
52-Wochen-Spanne:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
22.94 | 1.56B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
452.58 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.32 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.63 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.88 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.93 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
PLSE SEC FilingsPulse Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Swings: Is Pulse Biosciences Inc exposed to currency risks2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pulse Biosciences (PLSE) awards CTO 100,000 Restricted Stock Units - Stock Titan
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Australia
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference - businesswire.com
Pulse Biosciences Inc at JPMorgan Healthcare Conference Transcript - gurufocus.com
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - gurufocus.com
Q3 2025 Pulse Biosciences Inc Earnings Call Transcript - gurufocus.com
Q1 2025 Pulse Biosciences Inc Earnings Call Transcript - gurufocus.com
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences Shifts Focus to Catheter Electrophysiology Tech - Medical Product Outsourcing
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors - simplywall.st
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7%What's Next? - MarketBeat
PLSE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pulse Biosciences, Inc. 8-K SEC Filing March 23, 2026 – Company Information, NASDAQ Listing, and Key Details - Minichart
Pulse Biosciences Grants RSUs to Chief Technology Officer - TipRanks
Pulse Biosciences (NASDAQ: PLSE) awards CTO 100,000-share RSU grant - Stock Titan
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data - sharewise.com
PLSE Speeds Up Cardiac Catheter Initiative Following Landmark AFib Findings - Bitget
Stock Analysis: Is Pulse Biosciences Inc exposed to currency risks2026 Short Interest & Risk Managed Trade Strategies - baoquankhu1.vn
(PLSE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System - msn.com
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot - Sahm
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study - Yahoo Finance
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
What's Going With Pulse Biosciences Stock On Monday? - MSN
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones - MSN
Pulse Biosciences at Oppenheimer Conference: Promising AF Ablation Results By Investing.com - Investing.com India
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences shifts focus to cardiac catheter program By Investing.com - Investing.com South Africa
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter PlatformHas The Bull Case Changed? - simplywall.st
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results - Minichart
Pulse Biosciences Realigns Strategy Around nPulse AFib Platform - TipRanks
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program - Stock Titan
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - BioSpace
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program - marketscreener.com
Pulse Biosciences (PLSE) Prioritizes nPulse Cardiac Catheter Dev - GuruFocus
Pulse Biosciences shifts focus to cardiac catheter program - Investing.com
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.50%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):